Altum Sequencing
Contact information
- A. Health Biotechnology
- Areas of activity
- In vitro diagnostics
- Screening
- Therapeutic areas
- Oncology
- Blood and lymphatic system
- D. Services
- R&D services
- Bioinformatics
- Biotechnolgy kits
- Professional services
- Consultancy
Altum Sequencing – Providing doctors the right tools to save lives
At Altum Sequencing we revolutionize cancer monitoring after diagnosis and treatment. Using cutting-edge DNA sequencing, we can detect a single tumor cell among a million healthy ones—from just a simple blood sample.
While traditional imaging techniques can miss up to 40% of cases, our technology enables doctors to make faster decisions in real time, reduce healthcare costs and avoid invasive procedures for patients.
We empower doctors to personalize treatment: intensifying it when residual disease remains or reducing it when it’s safe—minimizing side effects and maximizing outcomes.
Our mission is to give every cancer patient the precise, tailored care they deserve.
Altum has created three key products that address one of the greatest unmet clinical needs in oncology: post-treatment cancer monitoring.
- CloneSight: a test based on genetic sequencing of liquid biopsy samples (blood or other fluids) that enables ultra-sensitive detection of Minimal Residual Disease (MRD) after cancer treatment, with very high sensitivity.
- ClonEv: test incorporating CloneSight technology for the detection of emerging or actionable mutations that may appear after treatment as a consequence of clonal evolution.
- AlloSight: unique solution in the market that combines in a single test the follow-up of MRD and the monitoring of specific markers derived from treatments or allogeneic transplants.
Portfolio of services:
- Liquid biopsy-based NGS testing: Clonesight, ClonEv and AlloSight.
- Tumor mutational screening: Genome sequencing, Exome and targeted panels for oncology and hematology.
- Molecular Diagnostics: We have more than 150 assays for oncology and hemato-oncology: point mutation detection by sequencing, gene overexpression and fusion detection by RT-PCR, clonality and microsatellite detection by fragment analysis.
- Pharmaceutical Industry, Biotechs, CROs, Researchers, Laboratories, Working Groups, Hospitals and doctors.
- Companies developing drugs seeking validation in clinical trials.
- Hematology and Oncology
Biotech Sanitaria
| Product / Service | Type | Therapeutic area | Development phase |
|---|---|---|---|
| Clonesight | Biomarkers, Diagnostic | Oncología | Clinical Validation |
| Clonesight | Biomarkers, Diagnostic | Oncología | Preclinical |
| Clonesight | Biomarkers, Diagnostic | Oncología | Clinical Validation |